1. Collins, J M., C. K. Grieshaber, and B. A. Chabner (1990). Review: Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Natl. Cancer Inst. 82, No. 16.
2. DiMasi, J. A., R. W. Hansen, H. G. Grabowski, and L. Lasagna (1991). Cost of innovation in the pharmaceutical industry, J. Health Econ. 10, 107–142.
3. Peck, C. C. (1992). Population approach in pharmacokinetics and pharmacodynamics: FDA view. In M. Rowland and L. Aarons (Eds.), New Strategies in Drug Development and Clinical Evaluation: Population Approach. Commission of European Communities, Brussels, pp. 157–168.
4. Peck, C. C., and J. M. Collins (1990). New drugs: The first time in man, a regulatory perspective, J. Clin. Pharmacol. 30, 210–222.
5. Sanathanan, L., and C. C. Peck (1991). The randomized concentration-controlled trial: An evaluation of its sample size efficiency. Controlled Clin. Trials 12, 780–794.